Abstract This retrospective analysis examined the pneumococcal serotype distribution of acute otitis media in Germany from 1995 to 2007. Data from the German National Reference Centre for Streptococci included 512 cases of pneumococcal otitis media in children and adults. Infections were mainly seen in children aged <5 years, who represented 67.0% of all reported cases. Most isolates (86.7%) were from spontaneous ruptures of the tympanum; 11.1% of the isolates were from otogenic sepsis or meningitis. Serotype 19F was the leading serotype (21.5%); serotype 3 (13.9%) was also often encountered. In children aged <5 years, the 7-valent, 10-valent, and 13-valent pneumococcal conjugate vaccines covered 54.3%, 60.2%, and 84.6% of the serotypes, respectively. Reduced penicillin susceptibility (minimum inhibitory concentration ≥0.1 mg/l) was seen in 11.0% of strains; 22.4% of strains were resistant to macrolides. Although based on a very limited selection of acute otitis media isolates, this analysis provides an estimate of the pneumococcal serotypes responsible for otitis media in Germany and underscores the need for future prospective studies.
Introduction
Streptococcus pneumoniae is a major pathogen in cases of acute otitis media (AOM), along with Haemophilus influenzae and Moraxella catarrhalis [1] . Of these three organisms, S. pneumoniae has been associated with more severe AOM signs and symptoms, greater virulence, and more complications [2] . To date, 91 distinct serotypes of S. pneumoniae have been identified, but only a few are responsible for most cases of AOM in young children, including serotypes 3, 6B, 9V, 14, 19F, and 23F [3, 4] .
The currently approved seven-valent pneumococcal conjugate vaccine (PCV7; Prevnar®/Prevenar® [Pfizer Inc, Philadelphia, PA]) includes purified capsular polysaccharides of seven serotypes of S. pneumoniae (4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to mutant diphtheria toxoid crossreactive material (CRM) 197 . In prelicensure trials, PCV7 demonstrated almost 100% efficacy against invasive pneumococcal disease (IPD) and some efficacy against AOM [5] . In the Northern California Kaiser Permanente trial in the United States (n=37,868 infants), PCV7 was 7% efficacious in preventing episodes of otitis media [5] . In the Finnish Otitis Media (FinOM) trial (n=1,662 infants), efficacy against AOM from any cause was 6% [6] . Long-term follow-up of these cohorts confirmed that receipt of PCV7 in infancy was associated with fewer otitis media physician visits and episodes [7] and a reduction in tympanostomy tube placement in children aged <12 months to 4-5 years [7, 8] . In a more recent publication, Shouval et al. reported that in children aged <3 years in Israel, PCV7, 10-valent vaccine, and 13-valent vaccine provided coverage of AOM of 54%, 59%, and 79%, respectively [9] . In a review by Rodgers et al., serotypes 6A, 6B, 14, 19A, 19F, and 23F were described as the most common serotypes in pneumococcal AOM among children worldwide [10] .
Although vaccine trials with PCV7 showed modest efficacy against AOM overall, there was considerable variation in serotype-specific efficacy. In the FinOM trial, PCV7 reduced the incidence of AOM due to vaccine serotypes by 57% overall. However, efficacy for specific serotypes ranged from 25% for serotype 19F to 84% for serotype 6B [6] .
Following generalized vaccination with PCV7 in the United States, at least three studies reported on the impact of immunization on the microbiology of AOM. These studies analyzed pre-and post-vaccination rates of middleear fluid (MEF) pathogen isolates and found that community use of PCV7 significantly reduced the overall proportion of S. pneumoniae isolates and vaccine serotypes causing AOM [11] [12] [13] . Data from the United States demonstrated that in a comparison of 2004 and 1997-1999 (baseline period), rates of ambulatory visits and antibiotic prescriptions attributable to AOM decreased by 42.7% and 41.9%, respectively [14] . Notably, the proportion of AOM infections due to nonvaccine pneumococcal strains and serogroups 6 and 19 increased over time [11, 13] .
In July 2006, the German Ständige Impfkomission (permanent committee on vaccination, STIKO) recommended vaccination with PCV7 for all children aged <2 years [15] . However, little is known about the epidemiology of pneumococcal otitis media in Germany [10, 16] , and no recent data are available on the serotype distribution of pneumococcal isolates from German children and adults with otitis media. Therefore, our study examined the pneumococcal serotype distribution related to AOM, using data from the German National Reference Centre for Streptococci.
Materials and methods
The database of the German National Reference Centre for Streptococci, which contains information on more than 25,000 cases of pneumococcal infections, was searched for cases of pneumococcal otitis media that occurred between 1995 and 2007. All S. pneumoniae isolates from ear swab and other isolates with the clinical diagnosis "acute otitis" or "mastoiditis" were included in the study. Duplicate isolates were excluded from the analysis.
Strains were obtained from (1) the study of IPD in children performed on a nationwide basis in Germany since 1996 (collaboration between the Robert Koch Institute, the ESPED [Erhebungseinheit für Seltene Pädiatrische Erkrankungen in Deutschland], and the National Reference Centre for Streptococci) [17] [18] [19] [20] [21] [22] , and (2) the nationwide surveillance of IPDs in adults [23] and upper respiratory tract infections in children and adults [17] . All studies were summarized in one database and made available for analysis.
Pneumococcal isolates were identified with standard microbiology methods, such as determination of optochin susceptibility and bile solubility. Strains were typed using the antisera provided by the Statens Serum Institut in Copenhagen, Denmark. A subgroup of all strains was tested for antibiotic sensitivity to penicillin G and clarithromycin (macrolide) using the Clinical and Laboratory Standards Institute (CLSI) guidelines for susceptibility testing [24] .
Results
A total of 512 isolates, mainly from children aged <2 years (34.4%), were included in the study. The remainder were from children aged ≥2 to <5 years (32.6%), ≥5 to <16 years (22.5%), and adults aged ≥16 years (10.5%). Sources of pneumococcal isolates are presented in Table 1 . Most cases (444 strains; 86.7% of isolates) were from children with spontaneous rupture of the tympanum (specimen was either pus from the middle ear or ear swab). In addition, three isolates from puncture of the mastoid and eight isolates from tympanocentesis were included in the study. There were 57 isolates (11.1%) from invasive disease (sepsis and meningitis). Even though it is highly likely that these children suffered from pneumococcal AOM, this was not microbiologically confirmed in all cases. Infections were more often seen in males (54.5% of strains).
Serotype data for all strains are presented in Fig. 1 . In our study, 19F was the leading serotype (21.5%), followed by serotypes 3 (13.9%), 14 (10.5%), and 23F (10.0%). Among children aged <5 years, the leading serotype was 19F (24.5%), followed by serotypes 14 (12.2%), 23F (11.4%), and 3 (8.7%) (Fig. 1) .
Coverage by serotypes included in the current and investigational pneumococcal conjugate vaccine formulations was evaluated. These formulations include PCV7 Table 2 . The coverage calculations were performed without accounting for possible cross-protection of serotype 6B towards serotype 6A, as described in some reports on PCV7 and the 10-valent vaccine [25, 26] . For children aged <5 years, coverage of PCV7 was 60.3% (n=207); the 10-valent vaccine, 63.6% (n=218); and the 13-valent vaccine, 85.4% (n=293). The cumulative coverage of the different pneumococcal conjugate vaccine formulations is presented in Fig. 2 . Antibiotic susceptibility data were available for 456 isolates. Reduced susceptibility to penicillin was seen in 11.0% of strains. This included a relatively high rate of strains (4.4%) with high-level penicillin G resistance (minimum inhibitory concentration [MIC] ≥2 mg/l). The rate of resistance to macrolides (clarithromycin) was 22.4% (Table 3) . Antibiotic susceptibility data were available for 304 strains isolated from children aged <5 years; 9.5% and 24.0% of these strains were found to be nonsusceptible to penicillin G and clarithromycin, respectively.
Characteristics of IPD in 33 children with otitis media (otogenic sepsis or meningitis) are presented in Table 4 . These cases were mainly seen in very young children (aged ≤1 year). The collection included 13 cases diagnosed from cerebrospinal fluid and 20 cases from blood. Among these infections, serotype 14 was the most common serotype (14 cases) followed by serotype 19A (4 cases). Serotype 19A is not included in PCV7 or the 10-valent pneumococcal conjugate vaccine. Of note, macrolide resistance was relatively common in those cases and occurred in more than a third of isolates.
Discussion
This study presents data on the serotype distribution of pneumococcal isolates from children and adults with spontaneously draining otitis media in Germany. The analysis included 512 cases, with 67.0% occurring in children aged <5 years. The results showed a relatively high rate of serotype 19F infections (21.5%), which is in accordance with the serotype distribution found in recent clinical studies and postlicensure surveillance of AOM in children in Finland [6] , the Czech Republic [27] , and the USA [28] . However, some differences in serotype distribution, particularly regarding serotype 23F infections, were [28] . Samples were collected between 1994 and 2000 from 3,232 children in the United States, Argentina, Finland, France, Greece, Israel, and several Eastern European countries. The results showed that the most common serotypes in each data set and age group tended to be the same, despite variations in location, data-set design, and antibiotic resistance. Serotypes 23F, 19F, and 14 were most prominent, each comprising about 13-16% of the overall data set [28] . Serotypes 6B, 6A, 19A, and 9V were less common, each comprising about 5-10% of all data sets. Serotypes 1, 5, and 7 contributed little (<2%) to overall pneumococcal AOM. Serotype 3 represented about 4% of the overall serotypes, and was most prominent in the youngest (<6 months) and oldest (≥60 months) age groups (approximately 5.8% and 21.5% of all isolates, respectively) [28] .
In contrast to these observations, our analysis of data from German children and adults showed a lower rate of serotype 23F infections (10.0%) and a higher rate of serotype 3 infections (13.9%). Globally, serotype 3 has become an increasingly significant MEF pathogen in children [10] . In German children aged <5 years, serotype 3 was found in 8.7% of cases. The coverage for the serotypes included in PCV7 (recommended for general use in children aged <2 years in Germany) was 60.3%, which was lower than the serotype coverage previously reported for IPD in Germany [18] . The inclusion of serotypes 1, 5, and 7F, which are in the 10-valent pneumococcal conjugate vaccine, increases the coverage by 3.3-63.6%. The 13-valent vaccine, which includes serotypes 3, 6A, and 19A in addition to the 10-valent vaccine serotypes, increases the coverage to 85.4%, mainly due to the inclusion of serotypes 3 and 19A (Fig. 2) .
Interestingly, we found a relatively high rate of reduced penicillin susceptibility (11.0%) in this study. This rate was higher than that previously reported with invasive disease in German children [18] . In addition, we found a high rate of macrolide resistance (22.4%), in accordance with rates reported for IPD in children in Germany [18, 19] . These high resistance rates may reflect the complexity of many of the cases, which included otitis media therapy failures.
Our study has some limitations. First, it covers a long period of time, and the power is low. Admittedly, more patients and data would have been useful for our analysis; unfortunately, we had no control over the number of the study population and were forced to rely only on the AOM serotype data available for Germany at the time of the study. A second limitation is the fact that microbiological diagnosis is not done on a routine basis in Germany. Consequently, the incidence of AOM in Germany is probably under-reported, because only a portion of the thousands of children who contract AOM in Germany each year are tested. Mild IPD may be under-diagnosed in several European countries, because blood cultures are not usually ordered for outpatients, who may be treated with no documentation of their febrile episodes. Blood cultures may not be ordered for inpatients with fever without focus or with pneumonia [29] . Lastly, pneumococcal isolates used in our study were identified with standard microbiology methods. Use of more specific techniques, such as polymerase chain reaction (PCR), would have improved identification of otitis media-associated bacteria.
Despite these limitations, our retrospective analysis of pneumococcal strains gathered the data needed to provide a rough estimate of the pneumococcal serotypes that cause otitis media associated with spontaneous drainage in Germany. This information will be invaluable when planning vaccination strategies to protect against otitis media.
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